一系列平面光环金属 ((II) 复合物作为新的抗癌治疗剂,诱导瘤症
Wenting Wang1, Pengchao Wang1, Xiali Liao1
1Faculty of Life Science and Technology, Kunming University of Science and Technology, Kunming 650500, P. R. China.
Journal of medicinal chemistry
|September 19, 2023
概括
四种新的 (II) 复合物显示出作为抗癌治疗剂的前景. 增加的芳香环增强了选择性,并使近红外和绿色辐射能够双重"打开",用于跟踪细胞相互作用并诱导癌症细胞死亡.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 癌症治疗方法 癌症治疗方法
背景情况:
- 循环金属 ((II) 复合物正在被探索用于抗癌应用.
- 治疗术剂结合了诊断和治疗能力.
- 连接体设计会影响复杂的特性,如脂性和细胞毒性.
研究的目的:
- 合成和评估新型平面环金属 ((II) 复合物 (1a-1d) 作为抗癌治疗剂.
- 为了研究连接体结构,脂性,细胞毒性和发光性质之间的关系.
- 评估细胞吸收,生物分子相互作用和癌症细胞死亡诱导机制.
主要方法:
- 合成和表征四种 (II) 复合物,具有扩大的芳香环.
- 对抗癌细胞系的细胞毒性的评估.
- 光谱分析 (NIR和绿色辐射) 用于监测Pt-Pt相互作用和生物分子结合 (BSA).
- 对焦成像用于追踪细胞局部 (核,溶酶体).
- 在Hela细胞中瘤诱导的研究.
主要成果:
- 复合物1a-1d表现出增加的脂性和选择性细胞毒性,随着芳香环的增加.
- 增强的近红外 (NIR) 辐射与酸盐缓冲盐水 (PBS) 中的Pt-Pt相互作用相关.
- 鲜明的"启动"绿色排放表明与牛血清白蛋白 (BSA) 结合,从1a降低到1d.
- 复合物1d在细胞核中呈现优先积累,并在Hela细胞中诱导显著的瘤.
- 复合体1b通过对焦成像在溶解体中定位.
结论:
- 合成的 (II) 复合体表现出异能潜力,其特性可通过联结体设计进行调整.
- 复合物1d是向癌症治疗的有希望的候选者,因为它具有细胞局部化和强大的瘤诱导作用.
- 双重发射特性为实时监测药物-生物分子相互作用和细胞命运提供了一个平台.
相关概念视频
Targeted Cancer Therapies
7.7K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.7K
Electron Transport Chain: Complex I and II
14.4K
The mitochondrial electron transport chain (ETC) is the main energy generation system in the eukaryotic cells. However, mitochondria also produce cytotoxic reactive oxygen species (ROS) due to the large electron flow during oxidative phosphorylation. While Complex I is one of the primary sources of superoxide radicals, ROS production by Complex II is uncommon and may only be observed in cancer cells with mutated complexes.
ROS generation is regulated and maintained at moderate levels necessary...
ROS generation is regulated and maintained at moderate levels necessary...
14.4K


